Mehta Meenu, Malyla Vamshikrishna, Paudel Keshav R, Chellappan Dinesh Kumar, Hansbro Philip M, Oliver Brian G, Dua Kamal
Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, New South Wales, Australia.
Centre for Inflammation, Centenary Institute, Sydney, New South Wales, Australia.
J Food Biochem. 2021 Nov;45(11):e13954. doi: 10.1111/jfbc.13954. Epub 2021 Oct 5.
Metastasis represents the leading cause of death in lung cancer patients. C-X-C Motif Chemokine Ligand 8 (CXCL-8), Chemokine (C-C motif) ligand 20 (CCL-20) and heme oxygenase -1 (HO-1) play an important role in cancer cell proliferation and migration. Berberine is an isoquinoline alkaloid isolated from several herbs in the Papaveraceae family that exhibits anti-inflammatory, anticancer and antidiabetic properties. Therefore, the aim of present study is to investigate the inhibitory potential of berberine monoolein loaded liquid crystalline nanoparticles (berberine-LCNs) against cancer progression. Berberine-LCNs were prepared by mixing berberine, monoolein and poloxamer 407 (P407) using ultrasonication method. A549 cells were treated with or without 5 µM dose of berberine LCNs for 24 hr and total cellular protein was extracted and further analyzed for the protein expression of CCl-20, CXCL-8 and HO-1 using human oncology array kit. Our results showed that berberine-LCNs significantly reduced the expression of CCl-20, CXCL-8 and HO-1 at dose of 5µM. Collectively, our findings suggest that berberine-LCNs have inhibitory effect on inflammation/oxidative stress related cytokines i.e. CCL20, CXCL-8, and HO-1 which could be a novel therapeutic target for the management of lung cancer. PRACTICAL APPLICATIONS: Berberine is an isoquinoline alkaloid extracted from various plants of Papaveraceae family. CXCL-8, CCL-20 and HO-1 play an important role in cancer progression. Our study showed that Berberine LCNs significantly downregulate the expression of CXCL-8, CCL-20 and HO-1 which suggests that Berberine loaded nanoparticles could be a promising therapeutic alternative for the management of lung cancer.
转移是肺癌患者的主要死因。C-X-C基序趋化因子配体8（CXCL-8）、趋化因子（C-C基序）配体20（CCL-20）和血红素加氧酶-1（HO-1）在癌细胞增殖和迁移中起重要作用。黄连素是从罂粟科几种草药中分离出的一种异喹啉生物碱，具有抗炎、抗癌和抗糖尿病特性。因此，本研究的目的是探讨黄连素单油酸酯负载液晶纳米粒（黄连素-LCNs）对癌症进展的抑制潜力。采用超声法将黄连素、单油酸酯和泊洛沙姆407（P407）混合制备黄连素-LCNs。用或不用5µM剂量的黄连素-LCNs处理A549细胞24小时，提取总细胞蛋白，并使用人类肿瘤学阵列试剂盒进一步分析CCl-20、CXCL-8和HO-1的蛋白表达。我们的结果表明，5µM剂量的黄连素-LCNs显著降低了CCl-20、CXCL-8和HO-1的表达。总体而言，我们的研究结果表明，黄连素-LCNs对炎症/氧化应激相关细胞因子即CCL20、CXCL-8和HO-1具有抑制作用，这可能是肺癌治疗的一个新的治疗靶点。实际应用：黄连素是从罂粟科多种植物中提取的一种异喹啉生物碱。CXCL-8、CCL-20和HO-1在癌症进展中起重要作用。我们的研究表明，黄连素-LCNs显著下调CXCL-8、CCL-20和HO-1的表达，这表明负载黄连素的纳米粒可能是肺癌治疗的一种有前景的治疗选择。
